tiprankstipranks
Trending News
More News >

Kindstar Globalgene Reports Revenue Decline and Net Loss for 2024

Story Highlights
Kindstar Globalgene Reports Revenue Decline and Net Loss for 2024

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Kindstar Globalgene Technology, Inc. ( (HK:9960) ).

Kindstar Globalgene Technology, Inc. reported a decrease in revenue by 4.1% for the year ended December 31, 2024, primarily due to changes in settlement models and a slight overall business revenue decline. The company experienced a net loss of RMB60.7 million, attributed to expected credit losses from extended receivable collection periods, fair value losses on fund investments, and the absence of non-recurring government subsidies received in the previous year. Despite these challenges, the gross profit margin improved due to refined product mix and cost control measures.

More about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. operates in the medical testing industry, offering a range of services including hematology, neurology, maternity-related, genetic disease, infectious disease, oncology testing, and more. The company is focused on providing comprehensive testing solutions and scientific research services.

YTD Price Performance: 18.64%

Average Trading Volume: 2,301,187

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.46B

For an in-depth examination of 9960 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1